Designer drugs 2015: assessment and management

Addiction Science & Clinical Practice

Michael F Weaver¹  John A Hopper²  Erik W Gunderson³ 

[1] The University of Texas Health Science Center at Houston, 1941 East Road, BBSB 1222, Houston, 77054, TX, USA

[2] St. Joseph Mercy Hospital, 5333 McAuley Drive, Suite R-3009, Ypsilanti, 48197-1014, MI, USA

[3] The University of Virginia, Center for Wellness and Change, 1007 East High Street, Charlottesville, 22902, VA, USA

关键词: Hallucinogens;    N-bomb;    25I-NBOMe;    Spice;    Synthetic cannabinoids;    Methylenedioxypyrovalerone;    Methylone;    Mephedrone;    Cathinones;    Bath salts;    Legal high;    Designer drugs;   

Others  :  1145161
DOI  :  10.1186/s13722-015-0024-7

 received in 2014-08-08, accepted in 2015-01-06,  发布年份 2015

【 摘 要 】

Recent designer drugs, also known as “legal highs,” include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as “bath salts”); synthetic cannabinoids (SCs; e.g., Spice); and synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability has evolved rapidly to evade legal regulation and detection by routine drug testing. Young adults are the primary users, but trends are changing rapidly; use has become popular among members of the military. Acute toxicity is common and often manifests with a constellation of psychiatric and medical effects, which may be severe (e.g., anxiety, agitation, psychosis, and tachycardia), and multiple deaths have been reported with each of these types of designer drugs. Clinicians should keep designer drugs in mind when evaluating substance use in young adults or in anyone presenting with acute neuropsychiatric complaints. Treatment of acute intoxication involves supportive care targeting manifesting signs and symptoms. Long-term treatment of designer drug use disorder can be challenging and is complicated by a lack of evidence to guide treatment.

【 授权许可】

   
2015 Weaver et al.; licensee BioMed Central.

【 参考文献 】

• [1]King LA, Kicman AT: A brief history of ‘new psychoactive substances’. Drug Test Anal 2011, 3:401-3.
• [2]Johnson LA, Johnson RL, Portier RB: Current “legal highs”. J Emerg Med 2013, 44:1108-15.
• [3]Kelly JP: Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 2011, 3:439-53.
• [4]Brandt SD, Sumnall HR, Measham F, Cole J: Analyses of second-generation ‘legal highs’ in the UK: initial findings. Drug Test Anal 2010, 2:377-82.
• [5]Wiegand TJ, Wax PM, Schwartz T, Finkelstein Y, Gorodetsky R, Brent J: The toxicology investigators consortium case registry—the 2011 experience. J Med Toxicol 2012, 8:360-77.
• [6]Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J: Mephedrone: use, subjective effects and health risks. Addiction 2011, 106:1991-6.
• [7]Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F: Mephedrone, new kid for the chop? Addiction 2011, 106:154-61.
• [8]Spiller HA, Ryan ML, Weston RG, Jansen J: Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol (Phila) 2011, 49:499-505.
• [9]Carhart-Harris RL, King LA, Nutt DJ: A web-based survey on mephedrone. Drug Alcohol Depend 2011, 118:19-22.
• [10]Hu X, Primack BA, Barnett TE, Cook RL: College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy 2011, 6:16. BioMed Central Full Text
• [11]Johnston L, O’Malley P, Miech R, Bachman J, Schulenberg J: Monitoring The Future National Survey Results on Drug Use: 1975-2013: Overview, Key Findings on Adolescent Drug Use. University of Michigan Institute for Social Research, Ann Arbor; 2014.
• [12]Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL: A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abus 2014, 35:184-9.
• [13]Dargan PI, Albert S, Wood DM: Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 2010, 103:875-9.
• [14]Camp NE: Synthetic cannabinoids. J Emerg Nurs 2011, 37:292-3.
• [15]Winstock AR, Barratt MJ: Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 2013, 131:106-11.
• [16]SAMHSA Center for Behavioral Health Statistics and Quality: The NSDUH Report: Trends in Adolescent Substance Use and Perception of Risk from Substance Use. Substance Abuse and Mental Health Services Administration, Rockville; 2013.
• [17]Vardakou I, Pistos C, Spiliopoulou C: Drugs for youth via internet and the example of mephedrone. Toxicol Lett 2011, 201:191-5.
• [18]Loeffler G, Hurst D, Penn A, Yung K: Spice, bath salts, and the U.S. military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. armed forces. Mil Med 2012, 177:1041-8.
• [19]Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al.: The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012, 37:1192-203.
• [20]Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M: Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 2013, 38:552-62.
• [21]Gunderson EW, Kirkpatrick MG, Willing LM, Holstege CP: Substituted cathinone products: a new trend in “bath salts” and other designer stimulant drug use. J Addict Med 2013, 7:153-62.
• [22]Hill SL, Thomas SH: Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 2011, 49:705-19.
• [23]Brunt TM, Poortman A, Niesink RJ, van den Brink W: Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 2011, 25:1543-7.
• [24]Sammler EM, Foley PL, Lauder GD, Wilson SJ, Goudie AR, O’Riordan JI: A harmless high? Lancet 2010, 376:742.
• [25]Davies S, Wood DM, Smith G, Button J, Ramsey J, Archer R: Purchasing ‘legal highs’ on the internet—is there consistency in what you get? QJM 2010, 103:489-93.
• [26]Weaver MF, Schnoll SH: In Addictions: A Comprehensive Guidebook. In Stimulants: amphetamines and cocaine. Edited by McCrady BS, Epstein EE. Oxford University Press USA, New York; 1999:105-20.
• [27]Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y: Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 2010, 198:31-8.
• [28]Harris CR, Brown A: Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 2013, 44:360-6.
• [29]Gunderson EW: Synthetic cannabinoids: a new frontier of designer drugs. Ann Inter Med 2013, 159:563-4.
• [30]Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL: “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 2012, 21:320-6.
• [31]Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N: ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009, 44:832-7.
• [32]Brewer TL, Collins M: A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. J Spec Pediatr Nurs 2014, 19:119-26.
• [33]Hurst D, Loeffler G, McLay R: Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 2011, 168:1119.
• [34]Muller H, Sperling W, Kohrmann M, Huttner HB, Kornhuber J, Maler JM: The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010, 118:309-10.
• [35]Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K: Withdrawal phenomena and dependence syndrome after the consumption of “spice gold”. Dtsch Arztebl Int 2009, 106:464-7.
• [36]Vandrey R, Dunn KE, Fry JA, Girling ER: A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 2012, 120:238-41.
• [37]Young AC, Schwarz E, Medina G, Obafemi A, Feng SY, Kane C: Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 2012, 30:1320. e5-7
• [38]Hopkins CY, Gilchrist BL: A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med 2013, 45:544-6.
• [39]Woo TM, Hanley JR: “How high do they look?”: identification and treatment of common ingestions in adolescents. J Pediatr Health Care 2013, 27:135-44.
• [40]Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D: AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 2013, 8:523-6.
• [41]Kazory A, Aiyer R: Synthetic marijuana and acute kidney injury: an unforeseen association. Clin Kidney J 2013, 6:330-3.
• [42]Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V: Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013, 108:534-44.
• [43]Mir A, Obafemi A, Young A, Kane C: Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011, 128:e1622-7.
• [44]Fattore L, Fratta W: Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 2011, 5:60.
• [45]Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R: Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 2006, 95:1308-17.
• [46]Vardakou I, Pistos C, Spiliopoulou C: Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010, 197:157-62.
• [47]Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM: 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 2013, 9:172-8.
• [48]Drug Enforcement AdministrationU.S. Department of Justice: Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order Fed Regist 2011, 76:65371.
• [49]Nichols DE, Frescas SP, Chemel BR, Rehder KS, Zhong D, Lewin AH: High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. Bioorg Med Chem 2008, 16:6116-23.
• [50]Rose SR, Poklis JL, Poklis A: A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol (Phila) 2013, 51:174-7.
• [51]Lawn W, Barratt M, Williams M, Horne A, Winstock A: The NBOMe hallucinogenic drug series: patterns of use, characteristics of users and self-reported effects in a large international sample. J Psychopharmacol 2014, 28:780-8.
• [52]Hill SL, Doris T, Gurung S, Katebe S, Lomas A, Dunn M: Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol (Phila) 2013, 51:487-92.
• [53]Stellpflug SJ, Kealey SE, Hegarty CB, Janis GC: 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl] ethanamine (25I-NBOMe): clinical case with unique confirmatory testing. J Med Toxicol 2014, 10:45-50.
• [54]Weaver MF, Schnoll SH: Hallucinogens and club drugs. In In The American Psychiatric Publishing Textbook of Substance Abuse Treatment. 4th edition. Edited by Galanter M, Kleber HD. American Psychiatric Press, Washington, DC; 2008:191-200.
• [55]Poklis JL, Devers KG, Arbefeville EF, Pearson JM, Houston E, Poklis A: Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl] ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int 2014, 234:e14-20.
• [56]Walterscheid JP, Phillips GT, Lopez AE, Gonsoulin ML, Chen H-H, Sanchez LA: Pathological findings in 2 cases of fatal 25I-NBOMe Toxicity. Am J Forensic Med Pathol 2014, 35:20-5.
• [57]Zamengo L, Frison G, Gregio M, Orru G, Sciarrone R: Determination of illicit drugs in seized materials: role of sampling and analysis in estimation of measurement uncertainty. Forensic Sci Int 2011, 208:108-23.
• [58]Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L: Spice: a never ending story? Forensic Sci Int 2009, 191:58-63.
• [59]Walker D, Neighbors C, Walton T, Pierce A, Mbilinyi L, Kaysen D: Spicing up the military: use and effects of synthetic cannabis in substance abusing army personnel. Addict Behav 2014, 39:1139-44.
• [60]Maxwell JC: Psychoactive substances-some new, some old: a scan of the situation in the U.S. Drug Alcohol Depend 2014, 134:71-7.
• [61]Gahlinger PM: Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine. Am Fam Physician 2004, 69:2619-26.
• [62]Chakraborty K, Neogi R, Basu D: Club drugs: review of the ‘rave’ with a note of concern for the Indian scenario. Indian J Med Res 2011, 133:594-604.
• [63]Gunderson EW, Kirkpatrick MG, Willing LM, Holstege CP: Intranasal substituted cathinone “bath salts” psychosis potentially exacerbated by diphenhydramine. J Addict Med 2013, 7:163-8.
• [64]Weaver M: Substance-related disorders. In In Textbook of Psychosomatic Medicine. 2nd edition. Edited by Levenson JL. American Psychiatric Press, Washington, DC; 2010:381-403.
• [65]Simmons J, Cookman L, Kang C, Skinner C: Three cases of “spice” exposure. Clin Toxicol (Phila) 2011, 49:431-3.
• [66]Haddad PM, Dursun SM: Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008, 23(Suppl 1):15-26.
• [67]Nunes EV, Levin FR: Treatment of co-occurring depression and substance dependence: using meta-analysis to guide clinical recommendations. Psychiatr Ann 2008, 38:730-738.
• [68]Martins SS, Copersino ML, Soderstrom CA, Smith GS, Dischinger PC, McDuff DR: Sociodemographic characteristics associated with substance use status in a trauma inpatient population. J Addict Dis 2007, 26:53-62.
• [69]Weaver MF, Jarvis MA, Schnoll SH: Role of the primary care physician in problems of substance abuse. Arch Intern Med 1999, 159:913-924.
• [70]McLellan AT, Lewis DC, O’Brien CP, Kleber HD: Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000, 284:1689-1695.
• [71]Hasin DS, Stinson FS, Ogburn E, Grant BF: Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2007, 64:830-842.
• [72]Maxwell JC, Spence RT: Profiles of club drug users in treatment. Subst Use Misuse 2005, 40:1409-1426.
• [73]Harwood H, Malhotra D, Villarivera C, Liu C, Chong U, Gilani J: Cost effectiveness and cost benefit analysis of substance abuse treatment: a literature review. In Cost Effectiveness and Cost Benefit Analysis of Substance Abuse Treatment: A Literature Review. The Lewin Group, Falls Church; 2002.